Company

Home > Company > History/Timeline

History/Timeline

Dec 2006 Business Started as JapanBridge
Jun 2007 Cooperation Agreement with Kyowa Hakko Kogyo Co., Ltd.(currently, Kyowa Hakko kirin Co., Ltd.) in oncology
Jan 2008 Establishment of Medical & Scientific Advisory Board
May 2008 License Agreement with ProStrakan for exclusive rights to Sancuso® in Japan, China, and other Asian territories
Sep 2008 Company name changed to Solasia Pharma K.K.
Apr 2009 Corporate office moved to Shiodome Building (Tokyo)
Jul 2009 Completion of SP-01 (Sancuso®) Japanese Phase I study
Feb 2010 License Agreement with Kyowa Hakko Kirin Co., Ltd. for the sublicense of Sancuso® in Taiwan, Hong Kong, Singapore & Malaysia
Mar 2011 License Agreement with ZIOPHARM Oncology Inc. for exclusive rights to darinaparsin in Japan, China, and other Asian territories
Dec 2011 Open Beijing Representative Office in China
Jan 2013 Open Shanghai Office in China
Nov 2013 Completion of SP-01 (Sancuso®) clinical pharmacological study targeting Chinese healthy adult patient in China
Dec 2013 Completion of subject enrollment in SP-02L (darinaparsin injection) Phase I study targeting Korean cancer patient
May 2014 Completion of SP-01 (Sancuso®) Phase III study targeting cancer patient with chemotherapy-induced nausea and vomiting in China
Jun 2014 Filing of New Drug Application (NDA) SP-01 (Sancuso®) in China
Jul 2014 License Agreement with ZIOPHARM Oncology Inc. for global license and collaboration for darinaparsin
Aug 2014 Completion of subject enrollment in SP-02L (darinaparsin injection) Phase I study targeting Japanese cancer patient
Dec 2014 Establishment of the subsidiary in Shanghai
Jan 2015 License Agreement with Meiji Seika Pharma for the development and commercialization of darinaparsin (intravenous formulation) in Japan.
Mar 2015 License and Distribution Agreement with Camurus for exclusive license of episil® in Japan and China
Nov 2015 License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of Sancuso® in China excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau and Taiwan.
Mar 2016 Asian Multinational Phase II study of SP-02L (darinaparsin injection) started.
May 2016 Filing of New Medical Device Application (NMDA) for episil® in China
Oct 2016 Filing of New Medical Device Application (NMDA) for episil® in Japan
Nov 2016 License and Collaboration Agreement With Meiji Seika Pharma for episil® in Japan